This study is currently recruiting participants.
National Institute of Allergy and Infectious Diseases (NIAID)
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 3 Years Max Age: 99 Years
Referral Letter Required
Taenia Solium; Neurocysticercosis; Tapeworm; Natural History
National Institute of Allergy and Infectious Diseases
Patients with suspected or confirmed cysticercosis may be eligible for this study. Participants will be hospitalized for 2 to 3 weeks and will take either praziquantel or albendazole by mouth for 2 weeks. They may receive a corticosteroid to lessen the side effects of the drug therapy. Patients will be evaluated with medically indicated tests and procedures that may include:
- Blood tests.
- X-rays of the head and long bones.
- Electroencephalogram - recording of the electrical activity of the brain
- Lumbar puncture (spinal tap) - examination of the cerebrospinal fluid that bathes the brain and spinal cord. For this procedure, a local anesthetic is given and a needle is inserted in the space between the bones (vertebrae) in the lower back. About 2 tablespoons of fluid is collected through the needle.
- Eye examination.
- Magnetic resonance imaging (MRI) to examine the brain. MRI uses a strong magnetic field and radio waves instead of X-rays to demonstrate structural and chemical changes in the brain. During the scan, the patient lies on a table in a narrow cylinder (the scanner). He or she can speak with a staff member via an intercom system at all times during the procedure.
- Computed tomography (CT) to examine the brain. CT can be done from different angles and allows the doctor to view the brain in small sections in 3-dimensions. The patient lies on a table with the head positioned in the CT scanner.
Some of the tests may be repeated on the last day of therapy and at 3 and 6 months or longer after therapy.
--Back to Top--
INCLUSION CRITERIA: 1. Patients ages 3 to 99 years. 2. Patients with proven or likely neurocysticercosis. 3. Willingness (of participant or legally authorized representative [LAR]) to sign consent and comply with study requirements. EXCLUSION CRITERIA: Not applicable.
1. Patients ages 3 to 99 years.
2. Patients with proven or likely neurocysticercosis.
3. Willingness (of participant or legally authorized representative [LAR]) to sign consent and comply with study requirements.
For more information: